María Sol Andrés

Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society

Alexander R. Lyon, Susan Dent, Susannah Stanway et al. · European Journal of Heart Failure · 2020 · 717 citations · Full text

Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer

Nicolò Matteo Luca Battisti, María Sol Andrés, Karla A. Lee et al. · Breast Cancer Research and Treatment · 2021 · 71 citations

Heart Failure, Breast Oncology, Cardiovascular Disease +6

The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment

María Sol Andrés, Sivatharshini Ramalingam, Stuart D. Rosen et al. · Cardio-Oncology · 2022 · 25 citations · Full text

Echocardiography versus Cardiac MRI for Measurement of Left Ventricular Ejection Fraction in Individuals with Cancer and Suspected Cardiotoxicity

Muhummad Sohaib Nazir, Joseph Okafor, Theodore Murphy et al. · Radiology Cardiothoracic Imaging · 2024 · 13 citations · Full text

Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score

Fiona Fernando, María Sol Andrés, Simone Claudiani et al. · Cardio-Oncology · 2024 · 13 citations · Full text